Replies to post #249469 on Biotech Values

[WorstLuck]

When the most vocal bulls stop announcing purchases is the more refined version of that sentiment indicator. Getting closer.

There is still more tax loss selling this month and more in December if it becomes relevant. Me, I'd rather wait on sales north of 25M in consecutive Q's even if it means buying at a higher price (and it might not.)

Getting ready for another tranche?

[jbog]

Dew,

I agree with much of you posted with the major disagreement being centered around

destined to make a lot of money for shareholders

Having a good product is the #1 goal for any company and revance can check that box, but sales and making money is a completely different story.

I know that any blog that people can post anonymous can be total BS and contaminated by others but there's 4 current threads on Cafeharma and if you can find one positive comment by a rep please point it out.


https://www.cafepharma.com/boards/forums/revance-biotech.1254/

[DewDiligence]

My forecasts for RVNC’s 3Q23/4Q23 revenue: #msg-173145191. FWIW

[Biowatch]

When some stocks keep hitting new lows, it’s not unexpected that some people will be unhappy and wish they’d sold at the high when they had the chance.

Buy low, sell high being a classic stock market mantra.

Buy and hold works best for companies that make net profits year after year.

[ciotera]

Re: "Daxxify is the best botulinum toxin on the market, and it will take a long time for competitors to produce something as good, if they can do it at all."

AbbVie is working on ABBV-950.

[alertmeipp]

$RVNC - down 20 percent last two days

Can the market be more negative on this one?

Supposed to be best in class drug.

EOLS which is selling an inferior product is having EV of 810mm with 2024 revenue guidance of 255mm. 3.2x multiple

RVNC minimum revenue guidance is 280mm. EV is 670mm. 2.4x.

I.e. the market is saying EOLS has better prospect than RVNC now. Make no sense to me.

Is it really that hard to roll out a product properly? They seems to execute well with RHA. How can they perform so messy with Daxxify?

Should Foley be fired?

[swampboots]

If the only thing I knew about RVNC was that they had the most superior Botulinum toxin on the market for years ahead, would that automatically confer/ bestow immediate stock value translated into, now at its current stock price and current management , is the compelling time to buy RVNC? And what argument would I use to duel with distractors who contend RVNC must dilute , to boost their financial' s by adjusting stock price lower with the value of those shares sold allowing them to remain solvent, insuring inflicting near term pain for current stock holders?

[Biowatch]

RVNC hits $4.45